DOES VIP TREATMENT CAUSE CANCER?  JAMES SCHALLER, MD TOP BEST RATED MD 54 PUBLICATIONS VASOACTIVE INTESTINAL
main page books and articles schaller health creed facebook testimonies search
menu main page what's new second opinion new patient meet doctor schaller location, travel

James Schaller, MD on VIP: Can it Increase Cancer? Useful?

First, VIP is an old and well researched protein that is the subject of a huge numbers of studies, patents and even advanced textbooks.

A physician in a very rural area of Maryland first mentioned it to me. And then I found a flood of information on it had already been done that had many uses.

The useful thing about VIP levels I have discovered is that many top labs can produce a result that is useful. That is not true of all anti-inflammation chemicals. Of course one needs to know the 2002-2004 reference range because some labs have dropped this reference range in the same way they have slowly dropped what is "acceptable" free T3 (potent thyroid) in the presence of an aging population with falling blood levels of T3.

My appeal would be that as more and more countries use VIP that the first few thousand be tracked with one question by their primary MD by the maker. Has this patient developed cancer, and if "Yes" what kind? No name need be given.

It is not that normalizing VIP is my concern in cancer risk. It is more that some of the pro-inflammatory things that might add to a decrease in VIP, may increase cancer risk. And that in a very small percent, would fixing this deficit add to a cancer risk. I am not sure.

A very small part of this question is the rare tumors that actually make VIP.

They are called, "VIPomas."

This unusual name stands for vasoactive intestinal peptide tumors.

The cancer cells are located rarely in the adrenal glands and most often located in the pancreas—it makes insulin and other hormones.

In later stages of the disease, VIPomas may spread to other organs.

But my concern is not based on these rare tumors, but on the impact of a patient with a cancer vulnerability, such as high fat estrogen metabolites like 16 OR 4--OH--Estrone, low CD8 or CD 57, or low Vitamin D or selenium levels, and then being given supplementation.

In conclusion, when this is finally available, and it is covered by insurance, which in the USA, means we are profoundly far away from routine use—real use is longer than past short appetizer duration studies. We will know more about this and other related topics in thousands of articles.

For years, the anti-inflammation effects seemed exciting, and each new month studies show new and fascinating dimensions of use. However, also at times, a study makes you realize that this is not air and water—it is not for everyone. And what might be good for one patient, or many patients, appears to make another disease do worse.

As for the issue of cancer, this issue only applies to those who have been told there is no way to increase their own VIP, which is highly rare, and those living in countries which allow for easier drug approval. When I find someone in those locations who cannot raise their VIP, I will do further study on this question: can supplemented VIP cause cancer or make a minority of medical troubles worse?

DR SCHALLER NEITHER SUPPORTS NOR OPPOSES THE USE OF VIP OUTSIDE THE USA. HE REGARDS FLAT LINE OR UNMEASURABLE VIP TO TYPICALLY BE A REVERSIBLE PROBLEM UNLESS SOMETHING(S) ARE MISSED THAT ARE UNDERMINING VIP PRODUCTION, AND THIS CAN BE DUE TO A GREAT MANY POSSIBLE CAUSES.


Bank Towers, Tamiami Trail, Naples, FL
disclaimer privacy